🟢 Cerenome is trading 18.18% up today after CNSide reported $1.55 million in Q3 billings

Cerenome is trading 18.18% up at $2.21 on October 1, 2026, following its September 30 business update on Q3 gross billings.

• CNSide billed 222 tests for $1.55 million in unaudited Q3 gross billings; initial cash collections are anticipated in Q4.
• The company highlighted progress on Medicare coverage and expansion of its testing menu. The figure is preliminary, represents charges submitted to payers, and is not GAAP revenue or confirmed collections.
• Broader healthcare shares were lower during the session.